ESR1 and breast carcinoma: Interestingly, Wang et al. examined the AXIN2 rs4791171 variant and reported a significant risk in younger patients with breast cancer (22); meanwhile, Alanazi et al. examined the AXIN2 rs3923086 variant and found a significant protective association for breast cancer in younger patients who also had the negative estrogen receptor subtype (21).